Chroma/CTI plan tosedostat PhIII to avoid AML trap that caught Vion, J&J and Genzyme
This article was originally published in Scrip
The mood of de-risking that prevails in the life sciences at the moment means that the transition of its lead compound tosedostat from Phase II studies to two Phase III registrational trials for acute myeloid leukaemia (AML) in 2012 is a crucial step for Chroma Therapeutics, the UK-based originator of the molecule and for Cell Therapeutics Inc., Chroma's US-based licensee for the Americas (North, South and Central).
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.